Enfortumab Vedotin Skin Reactions Linked to Longer Survival in Urothelial Cancer

A multi-institutional retrospective cohort study of 449 patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) found that 45.9% developed a cutaneous adverse event, most commonly pruritus, desquamating dermatitis, or morbilliform dermatitis. The study reported that EV-induced cutaneous adverse events were independently associated with improved progression-free survival (HR 0.60) and overall survival (HR 0.46) at the 30-day landmark, even after accounting for immortal time bias and concurrent immune checkpoint inhibitor exposure; high-grade reactions were not associated with worse survival.

Most relevant for: Patients with locally advanced or metastatic urothelial carcinoma receiving enfortumab vedotin, particularly those who develop treatment-related skin reactions.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.